Harvard Bioscience, Inc. (HBIO) IV/HV History
Comparing implied volatility to historical (realized) volatility reveals whether options are priced rich or cheap relative to actual price movement. Persistent gaps can signal trading opportunities.
Harvard Bioscience, Inc. (HBIO) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry, with a market capitalization near $24.9M, listed on NASDAQ, employing roughly 330 people, carrying a beta of 1.57 to the broader market. Harvard Bioscience, Inc. Led by John Duke, public since 2001-03-19.
Snapshot as of May 15, 2026.
- Spot Price
- $5.94
- ATM IV
- 200.4%
- HV 20-Day
- 118.8%
- HV 60-Day
- 110.7%
- IV Rank
- 41.3%
- IV Percentile
- 56.2%
As of May 15, 2026, Harvard Bioscience, Inc. (HBIO) ATM implied volatility is 200.4%. 20-day realized volatility is 118.8%, producing an IV-HV spread of +81.6 vol points. Options are pricing in more volatility than the stock has recently delivered, the volatility risk premium. IV rank is 41.3%.
How HBIO iv/hv history Data Feeds Strategy Selection
Strategy selection on Harvard Bioscience, Inc. options does not derive from any single metric in isolation. The iv/hv history view above sits inside a broader read: ATM IV currently sits at 200.4% and dealer gamma exposure is positive, so dealer hedging is mechanically mean-reverting. Combine the iv/hv history data here with the volatility-skew surface, dealer-gamma exposure, max-pain level, and upcoming-events calendar to build a positioning thesis. Risk-defined structures (credit spreads, debit spreads, iron condors) are usually safer than naked positions while the regime is uncertain; the data on this page anchors the inputs but does not by itself constitute a trade thesis.
Learn how implied vs realized volatility is reported and how to read the data →
Frequently asked HBIO iv/hv history questions
- Is HBIO options pricing rich or cheap right now?
- As of May 15, 2026, Harvard Bioscience, Inc. (HBIO) ATM IV is 200.4% against 20-day realized volatility of 118.8%. IV rank is 41.3%. HBIO options are pricing in more volatility than the stock has recently realized: a positive variance risk premium worth 81.6 vol points.
- What is the HBIO variance risk premium?
- The variance risk premium is the persistent gap between implied and subsequently realized volatility. In equity markets it averages positive because option sellers demand compensation for bearing variance shocks. HBIO is currently priced consistently with this premium, which is one input to whether short-vol or long-vol structures carry their typical edge.
- What does HBIO IV rank mean for strategy selection?
- IV rank normalizes the current ATM IV to its 1-year range: 0% is the low, 100% is the high. HBIO's current rank of 41.3% signals where current pricing sits in its own 1-year history. High-rank regimes typically favor premium-selling structures (credit spreads, condors, covered calls); low-rank regimes typically favor premium-buying or long-volatility structures.